Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Opthea Ltd

Initiate patient recruitment in the Phase 3 trials of OPT-302

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
22 Feb 2021
Due
31 Mar 2021
Delivered
by 31 Mar 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Patient recruitment in the Phase 3 trials is on-track to initiate in the 1Q CY 2021”
  • SourceOpthea Ltd Form 6-K press release, 2021-02-22
  • FilingSEC filing index
  • Deadline as statedin the 1Q CY 2021
  • Deadline used31 Mar 2021, the last day of the stated period
  • TypeProject
  • Permanent referenceKI-C-2021-CKDXF-024159
    Cite as https://keptindex.org/c/KI-C-2021-CKDXF-024159/ — this address never changes.

What we found

Evidence strength A What the grades mean

A 6-K filed 2021-03-31 refers to the continuation of Phase 3 patient recruitment, and a later 6-K in July 2021 says recruitment is underway, indicating the start by the March 2021 deadline.

  • A
    Opthea Ltd 6-K filed 2021-03-31 Regulatory filing · published 31 Mar 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “including, but not limited to, the continuation of patient recruitment for Opthea’s pivotal Phase 3 clinical trials of OPT-302 in wet AMD.” ✓ confirmed on the page
  • A
    Opthea Ltd 6-K filed 2021-07-06 Regulatory filing · published 6 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “Opthea is currently recruiting patients into two concurrent global, multi-center, randomized, double-masked, sham-controlled Phase 3 trials known as ShORe” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
Phase 3 ShORe and COAST trials of OPT-302 patient recruitment
In the company’s control
Medium
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Opthea Ltd? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-CKDXF-024159 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.